Andrew Zhu on Atezolizumab/Bevacizumab in HCC – The ASCO Post

AACR Virtual Annual Meeting 2020 Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses an exploratory analysis seeking to identify tumor-based molecular biomarkers that may be associated with clinical response or resistance to the combination treatment of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma…

Read the full article here

Related Articles